# Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma

> **NCT00916058** · PHASE1,PHASE2 · COMPLETED · sponsor: **Weill Medical College of Cornell University** · enrollment: 57 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Bendamustine
- **DRUG:** Melphalan
- **DRUG:** Bendamustine
- **DRUG:** Bendamustine
- **DRUG:** Bendamustine
- **DRUG:** Bendamustine
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT00916058
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04-23
- **Primary completion:** 2016-03-11
- **Final completion:** 2018-03-01
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2019-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00916058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00916058, "Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00916058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*